Coverage Decision Memorandum for Vagus Nerve Stimulation for Treatment of Resistant Depression
May 4, 2007 Coverage Decision Memorandum for Vagus Nerve Stimulation for Treatment of Resistant Depression The Centers for Medicare and Medicaid Services (CMS) said that the Vagus nerve stimulation device manufactured by Cyberonics did not improve depression outcomes enough to merit Medicaid coverage as an alternate treatment for medication-resistant depression. Despite refusing to cover the VNS therapy device for depression treatment, CMS spokespersons said that the agency is aware that there is a need for treatment options for people who do not respond to currently available and Medicare-approved depression treatments. CMS also said that it was not convinced . . .
